2025 MIT Health Science Forum: Treatment Effectiveness, New Biology Using AI – Enabled Nanosensor Technology (MIT Industrial Liaison Program – Startup Exchange)
Determining Treatment Effectiveness, Discovering New Biology Using AI – Enabled Nanosensor Technology
Freddy Nguyen
CEO & Co-Founder, Nine Diagnostics
See more of the 2025 MIT Health Science Forum here: https://ilp.mit.edu/Health25
Nine Diagnostics Joins American Cancer Society’s BrightEdge Entrepreneurs Program
Nine Diagnostics, a leader in AI-enabled nanosensor technology, has been selected to participate in the American Cancer Society’s BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate the most promising oncology-focused startups. This selection marks another significant milestone for Nine Diagnostics as it continues to drive innovation in cancer treatment selection, dosing, optimization, and monitoring.
Nine Diagnostics Selected for Merck Digital Sciences Studio Cohort 3
Arnold and Mabel Beckman Foundation – March 30, 2017
2017 Beckman Postdoctoral Fellow
Massachusetts Institute of Technology
Research: Development of nanosensors for in-vivo monitoring of cancer therapeutics
Freddy Nguyen, MD/PhD and Nine Diagnostics Win Novo Nordisk Golden Ticket at Pitch Event
Arnold and Mabel Beckman Foundation – March 30, 2017
2017 Beckman Postdoctoral Fellow
Massachusetts Institute of Technology
Research: Development of nanosensors for in-vivo monitoring of cancer therapeutics
Nine Diagnostics Wins Novo Nordisk Golden Ticket for LabCentral Residency
Arnold and Mabel Beckman Foundation – March 30, 2017
2017 Beckman Postdoctoral Fellow
Massachusetts Institute of Technology
Research: Development of nanosensors for in-vivo monitoring of cancer therapeutics
Nine Diagnostics
Determining treatment effectiveness, discovering new biology using AI enabled nanosensor technology.
A faster path to the most effective treatment with better outcomes. We develop holistic profiles based on a patient’s personal health data, demographics, social determinants of health, and other relevant factors pertinent to the ultimate outcomes.
Multidimensional datasets are acquired from fluorescent emissions using an array of nanoscale sensing elements that detect health abnormalities and signals of treatment effectiveness in small patient samples.
Role: Chief Executive Officer, Co-Founder